Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 22, 2022

Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With SGLT2 Inhibitors vs Metformin

Annals of Internal Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Internal Medicine
Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin: A Cohort Study
Ann. Intern. Med 2022 May 24;[EPub Ahead of Print], H Shin, S Schneeweiss, RJ Glynn, E Patorno

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading